Oddo BHF - SMA Solar Technology AG (S92) SMA Solar Technology AG : Le plan de restructuration est nécessaire mais pas suffisant sans la reprise de la demande

Report

Oddo BHF

Anis Zgaya ...

Louis Boujard, CFA

SMA Solar Technology AG : Le plan de restructuration est nécessaire mais pas suffisant sans la reprise de la demande

>Intégration du plan de restructuration en 2024, et estimations presque inchangées en 2025 et 2026 - Nous avons intégré le cout du plan de restructuration dans nos estimations 2024. Nous attendons désormais un CA de 1489 M€ en baisse de 5.3% par rapport à nos précédentes estimations (contre une nouvelle guidance entre 1450 M€ et 1500 M€), un EBITDA de -16.4 M€ contre 108 M€ précédemment (guidance entre -20 et 20 M€), un EBIT de -85 M€ (guidance entre -100 M€ et -50 M€...

15/11/2024 1 FR

Underlying

SMA Solar Technology AG

SMA Solar Technology is a holding company. Through its subsidiaries, Co. operates in five divisions: Medium Power Solutions, which distributes inverters, system solutions as well as products used for monitoring PV systems and energy management; Power Plant Solutions, which supplies central inverters and system solutions to PV plants; Service, which provides customers in Germany and abroad with support and after-sales services; Zeversolar, which serves the Chinese photovoltaic market and the budget market (low-price segment) in foreign markets; and Railway Technology, which manufactures converters as individual devices and energy supply systems for railway coaches.

See profile

DE000A0DJ6J9 Germany

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Anis Zgaya

Louis Boujard, CFA

Other Reports on these Companies

Oddo BHF

SMA Solar Technology AG : The restructuring plan is necessary but not sufficient without a recovery in demand

>Integration of the restructuring plan in 2024, and estimates almost unchanged in 2025 and 2026 - We factored the cost of the restructuring plan into our estimates for 2024. We now expect revenues of € 1,489m, down 5.3% on our previous estimates (versus new guidance for between € 1,450m and € 1,500m), EBITDA of -€ 16.4m versus € 108m previously (guidance between -€ 20m and € 20m), EBIT of -€ 85m (guidance between -€ 100m and -€ 50m) and an attributable net result of ...

1h / 27m 1h / 27m 1 EN

Oddo BHF

ODDO BHF Small & MIDCAP MORNING NEWS - Date1

We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...

22h / 2m 22h / 2m 1 FR

SCOR : Solvency margin much higher than expected

>Very good underlying profitability in P&C - Scor reported its Q3 2024 results yesterday. The group’s insurance revenues fell 6.8% l-f-l to € 3,944m, missing expectations, with declines of 2.5% in P&C (non-renewal of a multiyear contract, voluntary reduction at SBS) and 10.3% in life insurance. In P&C, the combined ratio was 88.3% (in line with the consensus and vs our estimate of 88.9%), with a nat cat cost of 13.2 points (vs 10 points budgeted) vs the consensus for...

39m 39m 1 EN

Oliver Metzger ... (+2)

Oliver Metzger
Stephan Wulf

Evotec SE : Halozyme confirmed a non-binding € 2bn offer – Looks attractive for Evotec shareholders

>Halozyme sees a good fit for both of Evotec’s business units - Halozyme Therapeutics, Inc. confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE to acquire Evotec for € 11.00 per share in cash, implying a fully diluted equity value of € 2.0bn. The proposal represents a premium of 27% to yesterday’s closing price and a premium of 77% to Evotec's last three-month volume weighted average price on 15 October 2024, th...

40m 40m 1 EN

Martin Marandon-Carlhian ... (+2)

Martin Marandon-Carlhian
Stephane Houri

ASML : Successful CMD, outlook broadly unchanged, but much more AI-exposed mix

>Outperform rating maintained after CMD, TP € 950, or 41% upside - ASML yesterday held its 2024 CMD, during which it reaffirmed its 2030 guidance (issued initially in 2022) for revenues of € 44-60bn and a gross margin of 56-60%. This confirmation, coming less a month after the warning on 2025, was a relief (stock at +7%), as the group’s long-term outlook remains as solid. We found the new management very clear on what has changed since 2022, i.e. negatives with market...

41m 41m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SMA Solar Technology AG : Le plan de restructuration est nécessaire mais pas suffisant sans la reprise de la demande

SMA Solar Technology AG : The restructuring plan is necessary but not sufficient without a recovery in demand

ODDO BHF Small & MIDCAP MORNING NEWS - Date1

SCOR : Solvency margin much higher than expected

Evotec SE : Halozyme confirmed a non-binding € 2bn offer – Looks attractive for Evotec shareholders

ASML : Successful CMD, outlook broadly unchanged, but much more AI-exposed mix

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe